Buspirone in the Treatment of Posttraumatic Stress Disorder

Authors

  • Dr. Barbara G. Wells Pharm.D.,

    Corresponding author
    1. Departments of Clinical Pharmacy, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
      Room 200, VA Medical Center, 26 South Dunlap Street, Memphis, TN 38163
    Search for more papers by this author
  • Dr. Chung-Chou Chu M.D.,

    1. Departments of Psychiatry, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author
  • Dr. Richard Johnson M.D.,

    1. Departments of Psychiatry, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author
  • Dr. Clifford Nasdahl Pharm.D.,

    1. Departments of Clinical Pharmacy, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author
  • Dr. Mohammed A. Ayubi M.D.,

    1. Departments of Psychiatry, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author
  • Dr. Edith Sewell Ph.D.,

    1. Departments of Psychiatry, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author
  • Dr. Paul Statham M.D.

    1. Departments of Psychiatry, University of Tennessee, Memphis
    2. VA Medical Center (all authors), Memphis Tennessee
    Search for more papers by this author

Room 200, VA Medical Center, 26 South Dunlap Street, Memphis, TN 38163

Abstract

Three patients with a DSM-III-R diagnosis of posttraumatic stress disorder were successfully treated with buspirone in final maximum dosages ranging from 35–60 mg daily. The onset of clinical efficacy ranged from 5–29 days. Symptoms that improved included anxiety, insomnia, flashbacks, and depressed mood. Patients experienced no side effects. Serotonin partial agonist effects are a possible mechanism underlying buspirone's efficacy.

Ancillary